| アブストラクト | OBJECTIVES: To evaluate and compare medication adherence and persistence for patients newly initiating single-inhaler triple therapy (SITT) and multiple-inhaler triple therapy (MITT) for chronic obstructive pulmonary disease (COPD) in Japan. DESIGN: Retrospective, new-user, active comparator, observational cohort study using inverse probability of treatment weighting. SETTING: Health insurance claims data from the Medical Data Vision Co., Ltd, hospital claims database. PARTICIPANTS: Adults diagnosed with COPD at age >/=40 years newly initiating MITT or SITT (fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or formoterol fumarate/budesonide/glycopyrronium) from 1 September 2019 to 31 July 2021. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome was medication adherence compared between patients using SITT and MITT, assessed by the proportion of days covered >/=80%. Secondary outcomes included medication persistence (time from index treatment initiation to discontinuation) compared between patients using SITT and MITT and medication adherence compared before and after the switch in a subgroup of patients switching from MITT to SITT. RESULTS: We included 2575 MITT and 2962 SITT users with similar baseline characteristics following weighting. The proportion of adherent patients was significantly greater for SITT versus MITT users at 6 months (19.7% vs 10.2%, p<0.0001), 12 months (6.0% vs 3.8%, p=0.0009) and 18 months (3.8% vs 1.4%, p<0.0001) post-index. Median persistence was also significantly higher for SITT versus MITT users (2.0 vs 1.0 months, p<0.001). Comparing specific SITT versus MITT, the proportion of adherent patients at each time point and median persistence was greater for FF/UMEC/VI. In patients switching from MITT to SITT (n=688), the proportion of adherent patients increased postswitch at the class level and for FF/UMEC/VI specifically. CONCLUSIONS: Patients with COPD in Japan who were newly initiating SITT had greater medication adherence and persistence compared with those on MITT up to 18 months following initiation. |
|---|
| ジャーナル名 | BMJ open |
|---|
| Pubmed追加日 | 2024/12/5 |
|---|
| 投稿者 | Joksaite, Sandra; Wood, Robert; Ismaila, Afisi; Camidge, Lucinda; Mizukami, Akiko; Czira, Alexandrosz; Massey, Olivia; Yarita, Masao; Compton, Chris; Siddiqui, Rad; Jennison, Thomas; Ishii, Takeo; Hashimoto, Kenichi; Rothnie, Kieran J |
|---|
| 組織名 | Value Evidence and Outcomes, R&D Global Medical, GlaxoSmithKline, London, UK.;Real-world Evidence, Adelphi Real World, Bollington, Cheshire, UK.;Value Evidence and Outcomes, R&D Global Medical, GlaxoSmithKline, Collegeville,;Pennsylvania, USA.;Department of Health Research Methods, Evidence, and Impact, McMaster University,;Hamilton, Ontario, Canada.;Value Evidence and Outcomes, Japan Medical and Development, GlaxoSmithKline,;Tokyo, Japan.;Global Medical, GlaxoSmithKline, London, UK.;Value Evidence and Outcomes, R&D Global Medical, GlaxoSmithKline, London, UK;kieran.j.rothnie@gsk.com. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39632104/ |
|---|
